Evaluation
*
HighAbove AverageAverageBelow AverageLow
Chris Campen, PharmD, BCPS, BCOP
Ali McBride, PharmD, BCPS, BCOP
Kelley Mayden, MSN, FHP, AOCNP
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Discuss the history and importance of biosimilars in oncology
Describe the current landscape of biotherapeutics in oncology
Discuss the current pathway for US Food and Drug Administration (FDA) approval of biosimilars
Define the potential clinical implications associated with biosimilars and biotherapeutics for advanced practitioners working in oncology
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*